Clik here to view.
VIVA 2015 Roundup: Medtronic touts Valiant stent graft, PAD stent-treatment data
Medtronic (NYSE:MDT) this week presented data from 2 studies of its stent systems and announced a new study of its In.Pact Admiral drug-coated balloon. The announcements were made at the VIVA...
View ArticleClik here to view.
Vascular Dynamics wins CE Mark for MobiusHD hypertension device
Vascular Dynamics said today it won CE Mark approval for its MobiusHD minimally invasive hypertension treatment device. The MobiusHD is a passive implant delivered percutaneously designed to amplify...
View ArticleClik here to view.
NuVasive co-founder McKinley is Vascular Dynamics new COO | Personnel Moves...
NuVasive co-founder McKinley is Vascular Dynamics new COO Vascular Dynamics said it tapped NuVasive Inc. (NSDQ:NUVA) co-founder and former CEO James McKinley as its new chief operating officer....
View ArticleClik here to view.
Vascular Dynamics raises $10m for MobiusHD
Vascular Dynamics said this week that it closed a private placement worth $10.4 million that it plans to use on the clinical program for its MobiusHD device for treating drug-resistant hypertension....
View ArticleClik here to view.
FDA approves pivotal study of Vascular Dynamics MobiusHD high blood pressure...
Vascular Dynamics said today that the FDA approved an investigational device exemption for a clinical trial of its MobiusHD device for treating resistant hypertension. MobiusHD is designed to help...
View ArticleClik here to view.
Vascular Dynamics touts significant BP reductions in interim MobiusHD trial...
Vascular Dynamics yesterday released interim results from the 1st-in-human trial of its MobiusHD implant designed for treating resistant hypertension, touting significant reductions in ambulatory...
View ArticleClik here to view.
Vascular Dynamics touts 6-month interim data from MobiusHD trial
Vascular Dynamics today released interim results from the 1st-in-human trial of its MobiusHD implant designed for treating resistant hypertension, touting a significant reduction in ambulatory...
View ArticleClik here to view.
Vascular Dynamics taps ex-Ellipse Tech CEO Roschak as chief exec | Personnel...
Vascular Dynamics said early this month it tapped former NuVasive Inc. (NSDQ:NUVA) exec and Ellipse Technologies CEO Ed Roschak as its new president and chief executive. Prior to joining Mountain View,...
View ArticleClik here to view.
AngioDynamics adds two to executive team | Personnel Moves
AngioDynamics (NSDQ:ANGO) added two new VPs to its executive team. The Albany, N.Y.-based device maker named Matthew Kapusta senior VP of business development and Donna Haire senior VP of regulatory,...
View ArticleClik here to view.
Vascular Dynamics raises $10m
Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it’s developing. The Mountain View, Calif.-based startup reported raising $9.7...
View ArticleClik here to view.
Vascular Dynamics reports raising $10 million in funding round | Medtech...
Vascular Dynamics raises $10m November 7, 2014 by Val Kennedy Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it’s developing. The...
View ArticleClik here to view.
Vascular Dynamics secures $17m Series B round
Vascular Dynamics said it secured $16.85 million in Series B financing to fund clinical trials for its device to treat drug-resistant hypertension. Under the agreement, VDI received $8.425 million up...
View ArticleClik here to view.
Vascular Dynamics launches pivotal trial for MobiusHD hypertension device
Vascular Dynamics said yesterday that it launched a pivotal trial of its MobiusHD device to treat high blood pressure ahead of a bid for a nod from the FDA. The MobiusHD device is designed to help...
View ArticleClik here to view.
ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board...
View Article
